Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

Speaker 3: (00:32)
Would you mind telling us a little bit about yourself and your background?

Speaker 3: (01:58)
Would you give us an overview of membranous nephropathy?

Speaker 3: (07:14)
Could you tell us a little bit about this new assay?

Speaker 3: (14:29)
Could you give a little example of how a clinician might use this information to treat their patients differently than how they would've in the past?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories.

They discuss Dr. Morice’s recent article in Becker’s Hospital Review, “Nine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025,” and go deeper into conversation about:

• The rapid evolution of artificial intelligence and large language models.
• Digital pathology.
• Proteomics, metabolomics, and mass spectrometry.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Erin Graf, Ph.D., co-director of Microbiology in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Arizona, to discuss benefits of automation in the laboratory.

Topics of discussion include:

• Specific examples of how they are using automation in the laboratory.
• Strategies for ensuring a smooth implementation and a positive experience for staff.
• The potential of automation to support staff and continued patient care excellence amid projected labor shortages in the future.